Jay Bhattacharya

A study on COVID-19 vaccine effectiveness, initially blocked from publication in a CDC journal, was published in JAMA Network Open. The study found vaccines reduced hospitalizations by 55% and emergency/urgent care visits by 50%, using a methodology criticized by CDC acting director Jay Bhattacharya but defended by public health researchers.

A study on the effectiveness of the COVID-19 vaccine, initially blocked from publication in a CDC journal, found the vaccine to be 55% effective against hospitalizations and 50% effective against emergency department/urgent care visits. The study, published in JAMA Network Open, used a test-negative design methodology, which CDC acting director Jay Bhattacharya criticized for potential flaws, though public health researchers defend its reliability.

NIH staffers published a dissent letter a year ago, urging a course correction they believed was needed for the agency. A year later, 71 staffers report NIH leadership 'largely ignored' their concerns and released a new report outlining nine ongoing issues with proposed solutions.

A Northwestern researcher and four others were removed from an American Diabetes Association conference for distributing an editorial critical of President Trump's attacks on scientific research. The group faced police intervention and had their materials confiscated, with the association citing code of conduct violations.

The CDC's flu vaccine advisory panel ACIP is suspended due to a federal judge's ruling, disrupting the usual process for vaccine recommendations. The Trump administration is attempting to reconstitute the panel amid legal challenges and uncertainty, while experts express concern over the lack of guidance for this year's immunization campaigns.

The article covers highlights from the American Diabetes Association's annual conference in New Orleans, including a keynote speech by Rick Woychik, a senior adviser to NIH chief Jay Bhattacharya, and discussions on newer GLP-1 drugs, research funding cuts, and a protest. The piece also mentions STAT+ content and invites readers to engage with the newsletter.

A senior NIH official endorsed the Make America Healthy Again (MAHA) movement at a diabetes research conference and defended criticism of biomedical research funding cuts. Richard Woychik, an adviser to NIH Director Jay Bhattacharya, stated he could have written the MAHA agenda, referencing Health Secretary Robert F. Kennedy Jr.'s policy.

Acting Director of the CDC Jay Bhattacharya stated that the Trump administration's response to the Ebola outbreak was more scientifically justified than the measures taken during the COVID-19 pandemic. He criticized lockdowns, school closures, and mask mandates as part of the COVID response.

Two simultaneous outbreaks of Ebola and hantavirus with high mortality rates are spreading globally with delayed detection and response. The article argues the Trump administration's dismantling of outbreak detection infrastructure has hampered the world's ability to contain these threats before they spread across borders.

Acting CDC Director Jay Bhattacharya issued quarantine orders preventing two cruise passengers from leaving a Nebraska facility to isolate at home, a decision that has drawn criticism from health experts. The strict measure reflects the Trump administration's hardline approach to Ebola containment protocols.

A Senate Appropriations Committee hearing on the NIH's fiscal year 2027 budget focused on immediate concerns including a leadership vacuum at the infectious disease institute, slow funding pace, and Trump administration policy impacts. NIH Director Jay Bhattacharya and five institute directors faced questions about these pressing issues rather than the proposed budget itself.

NIH Director Jay Bhattacharya is testifying before the Senate Appropriations Committee on President Trump's 2027 budget proposal, which includes a $5 billion cut to the agency and elimination of five of its 27 institutes. While these drastic proposals are unlikely to pass given lawmakers' previous rejection of even steeper 2026 cuts, the biomedical research community remains under significant stress.

NIH Director Jay Bhattacharya will testify before the Senate Appropriations Committee on Thursday regarding President Trump's fiscal 2027 budget request. The White House is proposing a $5 billion reduction in NIH funding, which includes cuts to grant and research programs.

NIH Director Jay Bhattacharya testified before the Senate Appropriations Subcommittee in a hearing session. The testimony covered matters related to the National Institutes of Health operations and funding.

Florida hospitals received significant Medicaid funding in a timely manner. The article mentions an upcoming NIH budget testimony by director Jay Bhattacharya before the Senate Appropriations Committee.

The National Institutes of Health has a leadership vacuum with 15 of 27 institutes led by acting directors, causing instability in long-term project planning and research funding priorities. The Department of Health and Human Services also has top leadership positions filled with acting directors. This lack of permanent leadership affects the research community and federal funding priorities.

An American woman, Angela Perryman, is being held against her will in a quarantine facility in Omaha, Nebraska, after potentially being exposed to hantavirus on a cruise ship. She has tested negative and is not showing symptoms but is being forced to stay for at least two more weeks. The quarantine order was issued under federal public health authority.

Marty Makary resigned as FDA Commissioner, leaving a vacancy at the agency's top position. This comes after a year of significant changes, including an announcement about Covid-19 vaccine recommendations. The resignation follows a period of challenges for the agency's drug and biologics divisions.

Dr. Jay Bhattacharya, director of the National Institutes of Health, discussed hantavirus risks with CBS Evening News. He is also acting director of the Centers for Disease Control and Prevention. The discussion focused on the potential threat to the U.S. public.

Jay Bhattacharya, acting director of the Centers for Disease Control and Prevention, stated that the hantavirus outbreak should be treated differently from COVID. The CDC leader downplayed the severity of the hantavirus outbreak. He compared it to a situation that does not warrant a high level of alarm.

Jay Bhattacharya, acting director of the Centers for Disease Control and Prevention, says the hantavirus outbreak should be treated differently from COVID. The statement was made to CBS News. The approach to the hantavirus outbreak is distinct.

Acting CDC Director Jay Bhattacharya discussed the US response to a hantavirus outbreak on a cruise ship, stating it's very different from COVID-19 and should be treated as such. The outbreak is being handled by the CDC. The agency's approach is under scrutiny.

Acting CDC Director Jay Bhattacharya comments on hantavirus outbreak, stating it is not COVID, after a Dutch cruise ship incident. The CDC has been communicating with the public as press attention increases. Hantavirus is a distinct virus from COVID.

The CDC has stated that the risk of hantavirus to the US public is very low amid an outbreak on a cruise ship headed to Europe, where three people have been affected. The outbreak involves a Dutch couple and a German national on board the M/V. The CDC is monitoring the situation.

The Acting CDC director delayed releasing a study that demonstrated the benefits of Covid vaccines. The article also mentions NIH Director Jay Bhattacharya speaking at the Conservative Political Action Conference.

The acting CDC director, Jay Bhattacharya, delayed the release of a report showing vaccines reduced ER visits and hospitalizations for healthy adults. Concerns arise that the delay may be part of efforts to undermine vaccine benefits.

The CDC delayed publishing a report on COVID-19 vaccine benefits at the request of acting director Jay Bhattacharya due to methodological concerns. The Washington Post reported this development, highlighting the delay's potential impact on public health discussions.

A CDC study highlighting significant health benefits from this season's COVID-19 vaccines was blocked from publication by acting CDC director Jay Bhattacharya. The move is attributed to Health Secretary Robert F. Kennedy Jr., an anti-vaccine advocate, raising concerns about political interference in scientific processes.